Author Page for Jorge Flores

Immune Responses to a Heterologous Booster with Mrna Based Covid-19 Vaccine after Priming with an Inactivated Newcastle Disease Virus Recombinant Vaccine Expressing the Sars-Cov-2 Spike Protein (Ndv-Hxp-S)

Number of pages: 30 Posted: 21 Jan 2025

Viravarn Luvira, Saranath Lawpoolsri Niyom, Weerapong Phumratanaprapin, Anan Jongkaewwattana, Sira Nanthapisal, Sant Muangnoicharoen, Supitcha Kamolratakul, Yupa Sabmee, Chatnapa Duangdee, Piengthong Narakorn, Surichan S, Laina Mercer, Rama Raghunandan, Christina Polyak, Ponthip Wirachwong, Jorge Flores and Punnee Pitisutthithum

Mahidol University - Institute of Human Righs and Peace Studies, Mahidol University, Mahidol University, National Center for Genetic Engineering and Biotechnology, Thammasat University, Mahidol University - Vaccine Trial Centre, Mahidol University, affiliation not provided to SSRN, Mahidol University, affiliation not provided to SSRN, affiliation not provided to SSRN, Institute for Disease Modeling, PATH, PATH, affiliation not provided to SSRN, PATH and Mahidol University - Vaccine Trial Centre

Downloads 45 (1,121,190)

Abstract:

2.

Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing Sars-Cov-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial

Number of pages: 26 Posted: 30 May 2024

Thiem Dinh Vu, Duc-Anh Dang, Vu Hai Ha, Nguyen Van Thom, Thang Cong Tran, Jose Mateus, Juan Manuel Carreño, Rama Raghunandan, Huong Mai Nguyen, Laina D. Mercer, Jorge Flores, E. Alexandar Escarrega, Ariel Raskin, Thai Huu Duong, Be Van Le, Alessandro Sette, Bruce L. Innis, Florian Krammer and Daniela Weiskopf

National Institute of Hygiene and Epidemiology, National Institute of Hygiene and Epidemiology, National Institute of Hygiene and Epidemiology, affiliation not provided to SSRN, PATH, La Jolla Institute for Allergy and Immunology (LIAI), affiliation not provided to SSRN, PATH, PATH, PATH, PATH, La Jolla Institute for Allergy and Immunology (LIAI), affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, La Jolla Institute for Allergy and Immunology (LIAI) - Division of Vaccine Discovery, PATH, Icahn School of Medicine at Mount Sinai - Department of Microbiology and La Jolla Institute for Allergy and Immunology (LIAI)

Downloads 41 (1,170,409)

Abstract:

3.

Safety and immunogenicity of Thailand Government Pharmaceutical Organization (GPO) produced, COVID-19 vaccine, 10 µg HXP-GPOVac: A Phase III, double-blind, randomized trial in comparison with VAXZEVRIA

Number of pages: 22 Posted: 26 Feb 2026

Ministry of Public Health, Thailand, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, PATH, Institute for Disease Modeling, PATH, PATH, PATH, Ministry of Public Health, Thailand, affiliation not provided to SSRN, Bureau of Policy and Strategy, Nonthaburi, Thailand, affiliation not provided to SSRN, affiliation not provided to SSRN, Government of the United States of America - Influenza Division and affiliation not provided to SSRN

Downloads 37 (1,222,651)

Jorge Flores

PATH

3

123

0

Scholarly Papers (3)

Immune Responses to a Heterologous Booster with Mrna Based Covid-19 Vaccine after Priming with an Inactivated Newcastle Disease Virus Recombinant Vaccine Expressing the Sars-Cov-2 Spike Protein (Ndv-Hxp-S)

Abstract:

Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing Sars-Cov-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial

Abstract:

Safety and immunogenicity of Thailand Government Pharmaceutical Organization (GPO) produced, COVID-19 vaccine, 10 µg HXP-GPOVac: A Phase III, double-blind, randomized trial in comparison with VAXZEVRIA

Abstract: